<?xml version="1.0" encoding="UTF-8"?>
<p id="Par2">Rheumatologists and clinicians world over are scrambling to advise and protect their patients from this infection. We know that patients with rheumatic and musculoskeletal diseases (RMDs), particularly those with systemic autoimmune diseases, are at increased risk of infections due to the RMD itself and due to immunosuppressive agents including corticosteroids and conventional synthetic, biologic, biosimilar and targeted synthetic disease modifying antirheumatic drugs (DMARDs). At present, however, there is no evidence that patients with RMD or patients on immunosuppressants fare worse in the COVID-19 pandemic than any other patient [
 <xref ref-type="bibr" rid="CR2">2</xref>]. Current recommendations state that patients should continue their current RMD therapy, because a flare in disease activity may follow discontinuation of therapy. Such flares may result in an increased risk of infection, may require corticosteroid therapy and may need medical attention increasing the probability of being in contact with healthcare facilities and therefore with the virus [
 <xref ref-type="bibr" rid="CR3">3</xref>, 
 <xref ref-type="bibr" rid="CR4">4</xref>].
</p>
